Health & Fitness
Health and Fitness
Health and Fitness
Wed, September 8, 2010
Tue, September 7, 2010
Rosetta Genomics to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
PHILADELPHIA & REHOVOT, Israel--([ BUSINESS WIRE ])--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer of microRNA-based molecular diagnostics, announced that Kenneth A. Berlin, president and chief executive officer, will be delivering a corporate overview on Tuesday, September 14, 2010 at 10:50 a.m. (Eastern time) at the Rodman & Renshaw 12th Annual Global Investment Conference taking place September 13-15, 2010 at the Palace Hotel in New York City.
"Navigating the Changing Regulatory Landscape of Laboratory Developed Tests"
Mr. Berlin will also be participating in a panel discussion entitled, aNavigating the Changing Regulatory Landscape of Laboratory Developed Testsa taking place on Tuesday, September 14th 2010 at 8:00 am in the Spellman Salon at the New York Palace Hotel.
Mr. Berlin will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Investment Conference. For those who would like to schedule an appointment with Rosetta Genomicsa™ management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [ afields@lhai.com ] or contact your Rodman & Renshaw representative.
The presentation will be webcast live at [ http://www.wsw.com/webcast/rrshq18/rosg ] and at the Investor Relations section of the Companya™s website at [ www.rosettagenomics.com ] where it will also be archived for 90 days.
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the companya™s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The companya™s first three microRNA-based tests, miRviewa" squamous, miRviewa" mets and miRviewa" meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit [ www.rosettagenomics.com ].
Forward-Looking Statements
Various statements in this release concerning Rosettaa™s future expectations, plans and prospects, including without limitation, statements relating to thedevelopment of early detection cancer screening products,including anon-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under aKey Information - Risk Factorsa in Rosettaa™s Annual Report on Form 20-F for the year ended December 31, 2009 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosettaa™s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
